These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28733827)

  • 1. Adding Adjuvant Systemic Treatment after Neoadjuvant Therapy in Breast Cancer: Review of the Data.
    Patel SA; DeMichele A
    Curr Oncol Rep; 2017 Aug; 19(8):56. PubMed ID: 28733827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
    Masuda N; Lee SJ; Ohtani S; Im YH; Lee ES; Yokota I; Kuroi K; Im SA; Park BW; Kim SB; Yanagita Y; Ohno S; Takao S; Aogi K; Iwata H; Jeong J; Kim A; Park KH; Sasano H; Ohashi Y; Toi M
    N Engl J Med; 2017 Jun; 376(22):2147-2159. PubMed ID: 28564564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study.
    Taşçı EŞ; Kutlu Y; Ölmez ÖF; Mutlu AU; Gündoğdu Y; Seyyar M; Şahin E; Çabuk D; Majidova N; Uğurlu İ; Demirci A; Aydın D; Çavdar E; Bayram S; Yıldırım N; Karataş F; Eryılmaz MK; Çağlayan D; Menekşe S; Kut E; Arak H; Keser M; Sunar V; Perkin P; Şakalar T; Oyan B; Sönmez Ö; Özer L; Yıldız İ
    Expert Opin Pharmacother; 2024 Mar; 25(4):477-484. PubMed ID: 38568074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
    Schneider BP; Jiang G; Ballinger TJ; Shen F; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Hancock BA; Kassem N; Helft P; O'Neil B; Storniolo AMV; Badve S; Miller KD; Radovich M
    J Clin Oncol; 2022 Feb; 40(4):345-355. PubMed ID: 34910554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials.
    Ye F; Bian L; Wen J; Yu P; Li N; Xie X; Wang X
    BMC Cancer; 2022 Mar; 22(1):261. PubMed ID: 35279130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials.
    Carey LA
    Clin Cancer Res; 2015 Sep; 21(18):4027-9. PubMed ID: 26374072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shifting Paradigms in TNBC Treatment: Emerging Alternatives to Capecitabine in the Post-Neoadjuvant Setting.
    Abahssain H; Souadka A; Alem R; Santoni M; Battelli N; Amela E; Lemaire A; Rodriguez J; Errihani H
    Curr Oncol; 2024 Jun; 31(7):3771-3782. PubMed ID: 39057150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials.
    Natori A; Ethier JL; Amir E; Cescon DW
    Eur J Cancer; 2017 May; 77():40-47. PubMed ID: 28355581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?
    Dülgar Ö; Öven BB; Atcı MM; Arıkan R; Ay S; Ayhan M; Selvi O; Ozyukseler DT; Bayram E; Özcan E; Yasin Aİ; Gümüş M
    Expert Rev Anticancer Ther; 2022 Jul; 22(7):773-780. PubMed ID: 35543015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation.
    Pelizzari G; Gerratana L; Basile D; Fanotto V; Bartoletti M; Liguori A; Fontanella C; Spazzapan S; Puglisi F
    Cancer Treat Rev; 2019 Jan; 72():7-14. PubMed ID: 30414986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy?
    Chaudhary LN; Wilkinson KH; Kong A
    Surg Oncol Clin N Am; 2018 Jan; 27(1):141-153. PubMed ID: 29132557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).
    Lluch A; Barrios CH; Torrecillas L; Ruiz-Borrego M; Bines J; Segalla J; Guerrero-Zotano Á; García-Sáenz JA; Torres R; de la Haba J; García-Martínez E; Gómez HL; Llombart A; Bofill JS; Baena-Cañada JM; Barnadas A; Calvo L; Pérez-Michel L; Ramos M; Fernández I; Rodríguez-Lescure Á; Cárdenas J; Vinholes J; Martínez de Dueñas E; Godes MJ; Seguí MA; Antón A; López-Álvarez P; Moncayo J; Amorim G; Villar E; Reyes S; Sampaio C; Cardemil B; Escudero MJ; Bezares S; Carrasco E; Martín M; ; ;
    J Clin Oncol; 2020 Jan; 38(3):203-213. PubMed ID: 31804894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.
    Promberger R; Dubsky P; Mittlböck M; Ott J; Singer C; Seemann R; Exner R; Panhofer P; Steger G; Bergen E; Gnant M; Jakesz R; Bago-Horvath Z; Rudas M; Bartsch R
    Clin Breast Cancer; 2015 Dec; 15(6):505-11. PubMed ID: 26195436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De-escalating and escalating systemic therapy in triple negative breast cancer.
    Carey LA
    Breast; 2017 Aug; 34 Suppl 1():S112-S115. PubMed ID: 28690105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons from the neoadjuvant setting on how best to choose adjuvant therapies.
    von Minckwitz G; Loibl S; Maisch A; Untch M
    Breast; 2011 Oct; 20 Suppl 3():S142-5. PubMed ID: 22015282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population.
    Beyerlin K; Jimenez R; Zangardi M; Fell GG; Edmonds C; Johnson A; Bossuyt V; Specht M; Mulvey TM; Moy B; Ellisen LW; Isakoff SJ; Bardia A; Spring LM
    J Oncol Pharm Pract; 2021 Dec; 27(8):1883-1890. PubMed ID: 33153384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adjuvant Capecitabine for Residual Disease after Standard Neoadjuvant Chemotherapy Among Patients with Triple-Negative Breast Cancer].
    Ishibashi Y; Hirano A; Yukawa H; Kitano A; Kodera A; Fujita S; Hattori A; Kamimura M; Shiozawa S
    Gan To Kagaku Ryoho; 2022 Dec; 49(13):1461-1463. PubMed ID: 36733102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials.
    Zhang ZC; Xu QN; Lin SL; Li XY
    PLoS One; 2016; 11(10):e0164663. PubMed ID: 27741288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
    Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
    PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.